NZ742805B2 - Anti-cd22 antibody-maytansine conjugates and methods of use thereof - Google Patents
Anti-cd22 antibody-maytansine conjugates and methods of use thereofInfo
- Publication number
- NZ742805B2 NZ742805B2 NZ742805A NZ74280516A NZ742805B2 NZ 742805 B2 NZ742805 B2 NZ 742805B2 NZ 742805 A NZ742805 A NZ 742805A NZ 74280516 A NZ74280516 A NZ 74280516A NZ 742805 B2 NZ742805 B2 NZ 742805B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- amino acid
- conjugate
- sequence
- fgly
- present
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 235000001014 amino acid Nutrition 0.000 claims 24
- 150000001413 amino acids Chemical class 0.000 claims 19
- XMTCKNXTTXDPJX-UHFFFAOYSA-N 3-oxoalanine Chemical compound O=CC(N)C(O)=O XMTCKNXTTXDPJX-UHFFFAOYSA-N 0.000 claims 15
- 125000000539 amino acid group Chemical group 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 5
- -1 aliphatic amino acid Chemical class 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Abstract
The present disclosure provides anti-CD22 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
Claims (29)
1. A conjugate of formula (I): (I) wherein W2 is an anti-CD22 antibody that includes at least one modified amino acid residue.
2. The conjugate of Claim 1, wherein the anti-CD22 antibody binds an epitope within amino acids 1 to 846, within amino acids 1-759, within amino acids 1-751, or within amino acids 1-670, of a CD22 amino acid sequence depicted in FIG. 8A-8C.
3. The conjugate of Claim 1, wherein the anti-CD22 antibody comprises a sequence of the formula (II): X 1 (FGly’)X2Z 20X 3Z 30 (II) wherein FGly’ is the modified amino acid residue of formula (I); Z 20 is either a proline or alanine residue; Z 30 is a basic amino acid or an aliphatic amino acid; X 1 may be present or absent and, when present, can be any amino acid, with the proviso that when the sequence is at the N-terminus of the conjugate, X1 is present; and X 2 and X3 are each independently any amino acid.
4. The conjugate of Claim 3, wherein the sequence is L(FGly’)TPSR. N O O OH O O N O OMe O NH O N O O O Cl OMe O N OH O N N N W2 142
5. The conjugate of Claim 3, wherein Z 30 is selected from R, K, H, A, G, L, V, I, and P; X 1 is selected from L, M, S, and V; and X 2 and X3 are each independently selected from S, T, A, V, G, and C.
6. The conjugate of Claim 1, wherein the modified amino acid residue is positioned at a Cterminus of a heavy chain constant region of the anti-CD22 antibody.
7. The conjugate of Claim 6, wherein the heavy chain constant region comprises a sequence of the formula (II): X 1 (FGly’)X2Z 20X 3Z 30 (II) wherein FGly’ is the modified amino acid residue of formula (I); Z 20 is either a proline or alanine residue; Z 30 is a basic amino acid or an aliphatic amino acid; X 1 may be present or absent and, when present, can be any amino acid, with the proviso that when the sequence is at the N-terminus of the conjugate, X1 is present; and X 2 and X3 are each independently any amino acid, and wherein the sequence is C-terminal to the amino acid sequence SLSLSPG.
8. The conjugate of Claim 7, wherein the heavy chain constant region comprises the sequence SPGSL(FGly’)TPSRGS.
9. The conjugate of Claim 7, wherein Z 30 is selected from R, K, H, A, G, L, V, I, and P; X 1 is selected from L, M, S, and V; and X 2 and X3 are each independently selected from S, T, A, V, G, and C.
10. The conjugate of Claim 1, wherein the modified amino acid residue is positioned in a light chain constant region of the anti-CD22 antibody. 143
11. The conjugate of Claim 10, wherein the light chain constant region comprises a sequence of the formula (II): X 1 (FGly’)X2Z 20X 3Z 30 (II) wherein FGly’ is the modified amino acid residue of formula (I); Z 20 is either a proline or alanine residue; Z 30 is a basic amino acid or an aliphatic amino acid; X 1 may be present or absent and, when present, can be any amino acid, with the proviso that when the sequence is at the N-terminus of the conjugate, X1 is present; and X 2 and X3 are each independently any amino acid, and wherein the sequence C-terminal to the sequence KVDNAL, and/or is N-terminal to the sequence QSGNSQ.
12. The conjugate of Claim 11, wherein the light chain constant region comprises the sequence KVDNAL(FGly’)TPSRQSGNSQ.
13. The conjugate of Claim 11, wherein Z 30 is selected from R, K, H, A, G, L, V, I, and P; X 1 is selected from L, M, S, and V; and X 2 and X3 are each independently selected from S, T, A, V, G, and C.
14. The conjugate of Claim 1, wherein the modified amino acid residue is positioned in a heavy chain CH1 region of the anti-CD22 antibody.
15. The conjugate of Claim 14, wherein the heavy chain CH1 region comprises a sequence of the formula (II): X 1 (FGly’)X2Z 20X 3Z 30 (II) wherein FGly’ is the modified amino acid residue of formula (I); Z 20 is either a proline or alanine residue; 144 Z 30 is a basic amino acid or an aliphatic amino acid; X 1 may be present or absent and, when present, can be any amino acid, with the proviso that when the sequence is at the N-terminus of the conjugate, X1 is present; and X 2 and X3 are each independently any amino acid, and wherein the sequence is C-terminal to the amino acid sequence SWNSGA and/or is Nterminal to the amino acid sequence GVHTFP.
16. The conjugate of Claim 15, wherein the heavy chain CH1 region comprises the sequence SWNSGAL(FGly’)TPSRGVHTFP.
17. The conjugate of Claim 15, wherein Z 30 is selected from R, K, H, A, G, L, V, I, and P; X 1 is selected from L, M, S, and V; and X 2 and X3 are each independently selected from S, T, A, V, G, and C.
18. The conjugate of Claim 1, wherein the modified amino acid residue is positioned in a heavy chain CH2 region of the anti-CD22 antibody.
19. The conjugate of Claim 1, wherein the modified amino acid residue is positioned in a heavy chain CH3 region of the anti-CD22 antibody.
20. A pharmaceutical composition comprising: a conjugate of any one of Claims 1 to 19; and a pharmaceutically acceptable excipient.
21. A use of the conjugate of any one of Claims 1 to 19 or the pharmaceutical composition of claim 20 in the manufacture of a medicament.
22. A use of the conjugate of any one of Claims 1 to 19 or the pharmaceutical composition of claim 20, in the manufacture of a medicament for treating cancer in a subject. 145
23. A use of the conjugate of any one of claims 1 to 19 or the pharmaceutical composition of claim 20, in the manufacture of a medicament for delivering a drug to a target site in a subject, wherein the medicament is to be administered to a subject, wherein the administering is effective to release a therapeutically effective amount of the drug from the conjugate at the target site in the subject.
24. The use of claim 22, wherein the cancer is a carcinoma, sarcoma, leukemia, or lymphoma.
25. The use of claim 24, wherein the lymphoma is B-cell lymphomas, Hodgkin’s lymphoma, or non-Hodgkin’s B cell lymphoma.
26. The conjugate of Claim 6, wherein the modified amino acid residue is positioned at a Cterminus of a heavy chain CH3 region of the anti-CD22 antibody,
27. The conjugate of Claim 26, wherein the heavy chain CH3 region comprises a sequence of the formula (II): X 1 (FGly’)X2Z 20X 3Z 30 (II) wherein FGly’ is the modified amino acid residue of formula (I); Z 20 is either a proline or alanine residue; Z 30 is a basic amino acid or an aliphatic amino acid; X 1 may be present or absent and, when present, can be any amino acid, with the proviso that when the sequence is at the N-terminus of the conjugate, X1 is present; and X 2 and X3 are each independently any amino acid, and wherein the sequence is C-terminal to the amino acid sequence SLSLSPG.
28. The conjugate of Claim 26, wherein the heavy chain CH3 region comprises the sequence SPGSL(FGly’)TPSRGS.
29. The conjugate of Claim 26, wherein 146 Z 30 is selected from R, K, H, A, G, L, V, I, and P; X 1 is selected from L, M, S, and V; and X 2 and X3 are each independently selected from S, T, A, V, G, and C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562252985P | 2015-11-09 | 2015-11-09 | |
PCT/US2016/060996 WO2017083306A1 (en) | 2015-11-09 | 2016-11-08 | Anti-cd22 antibody-maytansine conjugates and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ742805A NZ742805A (en) | 2023-12-22 |
NZ742805B2 true NZ742805B2 (en) | 2024-03-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4241847A3 (en) | Improved cell-targeting binding molecule | |
WO2015095301A3 (en) | Cytotoxic peptides and conjugates thereof | |
FI3389699T3 (en) | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof | |
MX2020002666A (en) | Anti- folate receptor alpha antibody conjugates and their uses. | |
WO2020056198A3 (en) | Substituted benzazepine compounds, conjugates, and uses thereof | |
WO2020236817A3 (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
MX2021005134A (en) | Cytostatic conjugates with integrin ligands. | |
MX2016016515A (en) | Auristatin derivatives and conjugates thereof. | |
RU2016129894A (en) | COVALENTLY RELATED HELICAR-ANTIBODY CONJUGATES AGAINST HELICAR AND THEIR APPLICATION | |
JP2017518304A5 (en) | ||
EP4306523A3 (en) | Imidazoquinoline compounds and uses thereof | |
RU2010145177A (en) | LIVER CANCER TREATMENT | |
MX2020010300A (en) | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof. | |
RU2016106339A (en) | ANTI-NER2 ANTIBODY AND ITS CONJUGATE | |
WO2018204872A3 (en) | Igf-1r monoclonal antibodies and uses thereof | |
CN106999540B (en) | Combination therapy | |
WO2020123836A9 (en) | Herboxidiene antibody-drug conjugates and methods of use | |
RU2018120696A (en) | ANTI-CD22 CONJUGATES ANTIBODY-MAYTANSIN AND WAYS OF THEIR APPLICATION | |
MX2022006519A (en) | Polyethylene glycol conjugate medicament, preparation method therfor and use thereof. | |
WO2018160178A8 (en) | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof | |
WO2017165822A8 (en) | Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | |
ZA202308282B (en) | Toxin molecule suitable for antibody-drug conjugate | |
KR20200126334A (en) | Adjuvant for cancer immunotherapy | |
PH12020500417A1 (en) | Anti-efgr antibody drug conjugates (adc) and uses thereof | |
WO2019131722A1 (en) | Conjugate of wt1-derived peptide and composition including same |